BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides

August 23, 2024

Sponsored By

What does the hiring of a well-known industry dealmaker mean for the future of BioMarin Pharmaceuticals? Can Eli Lilly's blockbuster obesity medicine lower the risk of diabetes? And will Recursion Pharma, the AI drug developer, live up to all the hype?

We discuss all that and more on this week's episode of "The Readout LOUD."

It's a guest-free episode this week, giving Allison, Adam and Elaine ample time to chat about the management shakeup at BioMarin, including the announcement that James Sabry, the former Roche dealmaker, was joining the company as its new chief business officer. We can't seem to go a week without talking about GLP-1 medicines, so in true form, Elaine walks us through new study findings that showed Lilly's Zepbound greatly reduced the risk of diabetes. We also discuss a separate study that potentially links GLP-1 drugs to a higher rate of suicidal thoughts.

Lastly, Adam and Elaine interrogate Allison about her deeply reported corporate profile of AI drug developer Recursion. Is all the hype real?

Listen Now

For more on Lilly's Zepbound diabetes study, go here. For a writeup of the suicide ideation study, look here. And Allison's sweeping profile of Recursion can be found here.